JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Blood

• Publication date

  2014-11-13

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/blood-2014-04-566687PMID 25193870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma

  2014cited by this paper
• Recurrent mutation of JAK3 in T‐cell prolymphocytic leukemia

  2014cited by this paper
• A unique case of refractory primary mediastinal B-cell lymphoma with JAK3 mutation and the role for targeted therapy

  2014cited by this paper
• Comprehensive Analysis of Transcriptome Variation Uncovers Known and Novel Driver Events in T-Cell Acute Lymphoblastic Leukemia

  2013cited by this paper
• JAK/STAT signaling in hematological malignancies

  2013cited by this paper
• Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia

  2013cited by this paper
• Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib

  2013cited by this paper
• Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent.

  2012cited by this paper
• The genetic basis of early T-cell precursor acute lymphoblastic leukaemia

  2012cited by this paper
• Predicting the Functional Effect of Amino Acid Substitutions and Indels

  2012cited by this paper
• High Accuracy Mutation Detection in Leukemia on a Selected Panel of Cancer Genes

  2012cited by this paper
• Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia

  2012cited by this paper
• JAK2 the future: therapeutic strategies for JAK-dependent malignancies.

  2012cited by this paper
• Mutation of the receptor tyrosine phosphatase PTPRC (CD45) in T-cell acute lymphoblastic leukemia.

  2012cited by this paper
• Janus kinase 3-activating mutations identified in natural killer/T-cell lymphoma.

  2012cited by this paper
• PTPN2 negatively regulates oncogenic JAK1 in T-cell acute lymphoblastic leukemia.

  2011cited by this paper
• MOHITO, a novel mouse cytokine-dependent T-cell line, enables studies of oncogenic signaling in the T-cell context

  2011cited by this paper
• Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia

  2011cited by this paper
• Jak1 has a dominant role over Jak3 in signal transduction through γc-containing cytokine receptors.

  2011cited by this paper
• FERM domain mutations induce gain of function in JAK3 in adult T-cell leukemia/lymphoma.

  2011cited by this paper
• Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.

  2010cited by this paper
• Discovery of CP-690,550: a potent and selective Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases and organ transplant rejection.

  2010cited by this paper
• JAK1 mutations are not frequent events in adult T‐ALL: a GRAALL study

  2010cited by this paper
• Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models.

  2009cited by this paper
• NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity.

  2009cited by this paper
• Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia

  2008cited by this paper
• Activating alleles of JAK3 in acute megakaryoblastic leukemia.

  2006cited by this paper
• Tyrosine kinases as targets for cancer therapy.

  2005cited by this paper
• Jak3 and the pathogenesis of severe combined immunodeficiency.

  2004cited by this paper

• Natural products for the treatment of ulcerative colitis: focus on the JAK/STAT pathway

  2025cites this paper
• JAK3A573V and JAK3M511I mutations in peripheral T-cell lymphoma mediating resistance to anti-PD-1 therapy through the STAT3/PD-L1 pathway

  2025cites this paper
• Models for T-large granular lymphocytic leukemia: how to mimic the cellular interplays in malignant autoimmunity

  2025cites this paper
• The JAK/STAT conundrum with mutational heterogeneity, immune defects, and the emergence of targeted therapies

  2025cites this paper
• Malignant JAK-signaling: at the interface of inflammation and malignant transformation

  2025cites this paper
• Major pathophysiological changes in pulmonary disease provided a molecular insight based on deep learning approach

  2025cites this paper
• Heritability and Transcriptional Impact of JAK3, STAT5A and STAT6 Variants in a Tyrolean Family

  2025cites this paper
• Drive to survive: gene dependency in T-cell acute lymphoblastic leukemia

  2024cites this paper
• Progression and perspectives in disease modeling for Juvenile myelomonocytic leukemia

  2024cites this paper
• Somatic genetic alterations of oncogenes and tumor suppressor genes in cholesteatoma

  2024cites this paper
• 芦可替尼联合维奈克拉及阿扎胞苷治疗伴JAK1、JAK3、STAT5B基因突变的难治性T-ALL患者1例报告并文献复习

  2024cites this paper
• Rhoifolin Attenuates Concanavalin A-Induced Autoimmune Hepatitis in Mice via JAKs/STATs Mediated Immune and Apoptotic Processes

  2024cites this paper
• Computational drug repositioning for IL6 triggered JAK3 in rheumatoid arthritis using FDA database

  2024cites this paper
• Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials

  2024cites this paper
• PIM1 is a potential therapeutic target for the leukemogenic effects mediated by JAK/STAT pathway mutations in T-ALL/LBL

  2024cites this paper
• Single-cell CRISPR screening characterizes transcriptional deregulation in T-cell acute lymphoblastic leukemia

  2024cites this paper
• Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions.

  2024cites this paper
• Synthesis, kinase inhibition and anti-leukemic activities of diversely substituted indolopyrazolocarbazoles.

  2024cites this paper
• Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency

  2024cites this paper
• The JAK3Q988P mutation reveals oncogenic potential and resistance to ruxolitinib

  2023influential citation
• In vitro and in vivo modelling of mutant JAK3/STAT5 signaling in leukemia

  2023cites this paper
• Partial response to venetoclax and ruxolitinib combination in a case of refractory T-prolymphocytic leukemia

  2023cites this paper
• Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer

  2023cites this paper
• JAK1 Pseudokinase V666G Mutant Dominantly Impairs JAK3 Phosphorylation and IL-2 Signaling

  2023cites this paper
• Understanding the Roles of the Hedgehog Signaling Pathway during T-Cell Lymphopoiesis and in T-Cell Acute Lymphoblastic Leukemia (T-ALL)

  2023cites this paper
• Integrating Clinical Cancer and PTM Proteomics Data Identifies a Mechanism of ACK1 Kinase Activation

  2023cites this paper
• JAK3 Mutations and Mitochondrial Apoptosis Resistance in T-Cell Acute Lymphoblastic Leukemia

  2022cites this paper
• Genomic profile of radiation-induced early-onset mouse B-cell lymphoma recapitulates features of Philadelphia chromosome-like acute lymphoblastic leukemia in humans.

  2022cites this paper
• Oncogenic TYK2 P760L kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade

  2022cites this paper
• Identification of U937JAK3-M511I Acute Myeloid Leukemia Cells as a Sensitive Model to JAK3 Inhibitor

  2022cites this paper
• New Agents for the Treatment of T-Cell Acute Lymphoblastic Leukemia

  2022cites this paper
• Targeting Leukemia-Initiating Cells and Leukemic Niches: The Next Therapy Station for T-Cell Acute Lymphoblastic Leukemia?

  2022cites this paper
• Discovery of Hexahydrofuro[3,2-b]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant.

  2022cites this paper
• Clinical, Diagnostic and Prognostic Characteristics of Primary Cutaneous Gamma Delta T-cell Lymphomas

  2022cites this paper
• Therapeutic approaches for relapsed/refractory adult acute lymphoblastic leukemia (ALL), a review on monoclonal antibodies and targeted therapies

  2022cites this paper
• In vivo impact of JAK3 A573V mutation revealed using zebrafish

  2022influential citation
• Adenylate kinase 2 expression and addiction in T-ALL.

  2021cites this paper
• Untwining Anti-Tumor and Immunosuppressive Effects of JAK Inhibitors—A Strategy for Hematological Malignancies?

  2021cites this paper
• Deregulation of the Interleukin-7 Signaling Pathway in Lymphoid Malignancies

  2021influential citation
• Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma

  2021cites this paper
• Current and emerging therapeutic approaches for T‐cell acute lymphoblastic leukaemia

  2021cites this paper
• Germline RUNX1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia

  2021cites this paper
• Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma

  2021cites this paper
• Janus Kinases in Leukemia

  2021cites this paper
• Working and safety profiles of JAK/STAT signaling inhibitors. Are these small molecules also smart?

  2021cites this paper
• JAK3 Is Expressed in the Nucleus of Malignant T Cells in Cutaneous T Cell Lymphoma (CTCL)

  2021cites this paper
• Leukemia: Trends in treatment and how close we have achieved eradication

  2021cites this paper
• Reactive Oxygen Species in Acute Lymphoblastic Leukaemia: Reducing Radicals to Refine Responses

  2021cites this paper
• Oncogenic Cooperation Between IL7R-JAK-STAT Pathway Mutations

  2021cites this paper
• PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression

  2021cites this paper
• Oncogenic cooperation between TCF7-SPI1 and NRAS(G12D) requires β-catenin activity to drive T-cell acute lymphoblastic leukemia

  2021cites this paper
• PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia

  2021cites this paper
• Adult T-cell acute lymphoblastic leukemias with IL7R pathway mutations are slow-responders who do not benefit from allogeneic stem-cell transplantation

  2020cites this paper
• Identifying Genetic Lesions in Ocular Adnexal Extranodal Marginal Zone Lymphomas of the MALT Subtype by Whole Genome, Whole Exome and Targeted Sequencing

  2020cites this paper
• Identification Of A Novel Single Amino Acid Substitution (v666g) Of JAK1 From A Patient With Acute Lymphoblastic Leukemia Impairs JAK3 Mediated Il-2 Signaling

  2020cites this paper
• Current understandings on T-cell prolymphocytic leukemia and its association with TCL1 proto-oncogene.

  2020cites this paper
• Ruxolitinib is effective in the treatment of a patient with refractory T‐ALL

  2020cites this paper
• Failure of tofacitinib to achieve an objective response in a DDX3X-MLLT10 T-lymphoblastic leukemia with activating JAK3 mutations

  2020cites this paper
• Activating JAK-mutations confer resistance to FLT3 kinase inhibitors in FLT3-ITD positive AML in vitro and in vivo

  2020cites this paper
• Old Drugs for JAK-STAT Pathway Inhibition in COVID-19

  2020cites this paper
• Cellular origins and genetic landscape of cutaneous gamma delta T cell lymphomas

  2020cites this paper
• Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma

  2020cites this paper
• Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T-cell lymphoma expressing the ITK-SYK fusion gene

  2019influential citation
• The regulation of JAKs in cytokine signaling and its breakdown in disease.

  2019cites this paper
• IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update

  2019cites this paper
• Overexpression of CD59 inhibits apoptosis of T-acute lymphoblastic leukemia via AKT/Notch1 signaling pathway

  2019cites this paper
• Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?

  2019cites this paper
• Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases

  2019cites this paper
• Are peptides a solution for the treatment of hyperactivated JAK3 pathways?

  2019cites this paper
• Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

  2019cites this paper
• Peripheral T-Cell Lymphoma: Moving Toward Targeted Therapies.

  2019cites this paper
• Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia

  2019cites this paper
• Targeting steroid resistance in T-cell acute lymphoblastic leukemia.

  2019cites this paper
• Suz12 inactivation cooperates with JAK3 mutant signaling in the development of T-cell acute lymphoblastic leukemia.

  2019cites this paper
• New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia.

  2019cites this paper
• The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.

  2019influential citation
• JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

  2019cites this paper
• Identification of Target Associations for Polypharmacology from Analysis of Crystallographic Ligands of the Protein Data Bank

  2019cites this paper
• Ruxolitinib Synergizes With Dexamethasone for the Treatment of T-cell Acute Lymphoblastic Leukemia

  2019cites this paper
• JAK/STAT Pathway Mutations in T-ALL, Including the STAT5B N642H Mutation, are Sensitive to JAK1/JAK3 Inhibitors

  2019cites this paper
• A Novel Selective JAK2 Inhibitor Identified Using Pharmacological Interactions

  2018cites this paper
• Hyperactivation of Oncogenic JAK3 Mutants Depend on ATP Binding to the Pseudokinase Domain

  2018influential citation
• JAK3 mutations and HOXA9 expression are important cooperating events in T-cell acute lymphoblastic leukemia

  2018cites this paper
• Cooperative Enhancer Activation by TLX1 and STAT5 Drives Development of NUP214-ABL1/TLX1-Positive T Cell Acute Lymphoblastic Leukemia

  2018cites this paper
• STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma

  2018cites this paper
• Animal models of T-cell acute lymphoblastic leukemia: mimicking the human disease

  2018cites this paper
• HOXA9 Cooperates with Activated JAK/STAT Signaling to Drive Leukemia Development.

  2018cites this paper
• Single-cell sequencing reveals the origin and the order of mutation acquisition in T-cell acute lymphoblastic leukemia

  2018cites this paper
• Mutant JAK3 signaling is increased by loss of wild-type JAK3 or by acquisition of secondary JAK3 mutations in T-ALL.

  2018cites this paper
• Double sword role of EZH2 in leukemia.

  2018cites this paper
• Partial trisomy 21 contributes to T-cell malignancies induced by JAK3-activating mutations in murine models.

  2018cites this paper
• Using immunotherapy to boost the abscopal effect

  2018cites this paper
• Genomic Profiling of T-Cell Neoplasms Reveals Frequent JAK1 and JAK3 Mutations With Clonal Evasion From Targeted Therapies

  2018cites this paper
• Advances in the genetics of acute lymphoblastic leukemia in adults and the potential clinical implications

  2018cites this paper
• Driver genes in CTCL : a genomic approach for screening and a detailed analysis of a candidate gene

  2017cites this paper
• Interleukin-7 signaling as a therapeutic target in acute lymphoblastic leukemia

  2017cites this paper
• The ba/f3 transformation assay: characterization of a novel csf2rb-activating variant, and the discovery of acquired mutations in ba/f3 cells

  2017cites this paper
• Targeted Therapy and Precision Medicine

  2017cites this paper
• Targeted therapies for T‐cell acute lymphoblastic leukaemia (T‐ALL): what makes T‐ALL TYK?

  2017cites this paper
• Analysis of acquired mutations in transgenes arising in Ba/F3 transformation assays: findings and recommendations

  2017influential citation